A clinical trial update dated July 22, 2026 reports on the study titled Sequential Therapies After Osteoanabolic Treatment, registered as NCT06164795. Teriparatide is the compound named in connection with this osteoanabolic treatment research. According to the update, the trial status is listed as recruiting. No phase was specified in the available data for this listing.
The study is registered on ClinicalTrials.gov, and its record reflects the current recruitment status as of the update date. No outcome data, efficacy results, or safety findings were included in this update. The event data provided does not describe results, interim findings, or conclusions of any kind. Only the trial title, its registration status as recruiting, and the date of the update are confirmed by the available information.
Readers interested in the design or purpose of the study can consult the official trial registration for further details, as this brief does not extend beyond the confirmed status update. Additional information about study arms, enrollment criteria, or comparator treatments was not part of the data supplied for this report.
For more background on this compound, readers can consult the teriparatide overview.